# EDGAR Filing Document

**Accession Number:** 0001388658
**File Stem:** 0001388658-26-000009
**Filing Date:** 2026-2
**Character Count:** 26651
**Document Hash:** 525cda9dfe179f4b1de9f994bcb12adf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001388658-26-000009.hdr.sgml**: 20260219

**ACCESSION NUMBER**: 0001388658-26-000009

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260219

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260219

**DATE AS OF CHANGE**: 20260219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iRhythm Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001388658
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 413421287
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37918
- **FILM NUMBER:** 26654560

**BUSINESS ADDRESS:**
- **STREET 1:** 699 8TH STREET
- **STREET 2:** SUITE 600
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94103
- **BUSINESS PHONE:** 415-632-5700

**MAIL ADDRESS:**
- **STREET 1:** 699 8TH STREET
- **STREET 2:** SUITE 600
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** iRhythm Technologies, Inc.
- **DATE OF NAME CHANGE:** 20111021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IRhythm Technologies, Inc.
- **DATE OF NAME CHANGE:** 20110429

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IRhythm Technologies Inc
- **DATE OF NAME CHANGE:** 20070201

?xml version='1.0' encoding='ASCII'? irtc-20260219

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): February 19, 2026**

**iRhythm Holdings, Inc.** 

**(Exact name of Registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37918** | **41-3421287** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification Number)** |

---

**699 8th Street, Suite 600** 

**San Francisco, California 94103** 

**(Address of principal executive office) (Zip Code)**

**(415) 632-5700** 

**(Registrant's telephone number, including area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, Par Value $0.001 Per Share | IRTC | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. Results of Operations and Financial Condition.**

On February 19, 2026, iRhythm Holdings, Inc. issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 2.02, including Exhibit 99.1 to this Form 8-K, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "<u>Securities Act</u>"). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits**

**(d)** **Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release issued by iRhythm Holdings, Inc., dated as of February 19, 2026](irtcq42025ex991pressrelease.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **IRHYTHM HOLDINGS, INC.** | **IRHYTHM HOLDINGS, INC.** |
| Date: February 19, 2026 | By: | /s/ Daniel G. Wilson |
|  |  | Daniel Wilson |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**iRhythm Holdings Announces Fourth Quarter and** 

**Full Year 2025 Financial Results**

**SAN FRANCISCO, February 19, 2026 (GLOBE NEWSWIRE)** -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2025.

**Fourth Quarter 2025 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of $208.9 million, a 27.1% increase compared to fourth quarter 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross margin of 70.9%, a 90-basis point increase compared to fourth quarter 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income of $5.6 million, a $6.9 million improvement compared to fourth quarter 2024 and the first quarter of positive GAAP net income in Company history

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA and adjusted EBITDA margin of $34.3 million and 16.4%, respectively, a $15.0 million and 470-basis point improvement, respectively, compared to fourth quarter 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Unrestricted cash, cash equivalents and marketable securities of $583.8 million at December 31, 2025, a $18.6 million increase from September 30, 2025

**Full Year 2025 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of $747.1 million, a 26.2% increase compared to full year 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross margin of 70.6%, a 170-basis point increase compared to full year 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss of $44.6 million, a $68.7 million improvement compared to full year 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA and adjusted EBITDA margin of $68.9 million and 9.2%, respectively, a $76.7 million and 1,050-basis point improvement, respectively compared to full year 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Free cash flow of $34.5 million, the first year of positive free cash flow in Company history

**Recent Operational Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Record quarterly revenue and fifth consecutive quarterly revenue above 20% year-over-year growth, driven by volume across our US core business, innovative health channels, and international markets

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Upcoming data presentations at the American College of Cardiology's Annual Scientific Session & Expo in New Orleans, Louisiana, from March 28 – 30, 2026

"The fourth quarter capped a transformational year for iRhythm," said Quentin Blackford, President and Chief Executive Officer of iRhythm. "In 2025, we delivered strong revenue growth, meaningfully expanded margins, and achieved positive quarterly GAAP net income for the first time in our history — milestones that reflect both the strength of our execution and the durability of our business model. Demand for Zio continues to broaden across cardiology, primary care, and innovative channel partnerships as health systems and payers increasingly recognize the value of proactive, data-driven arrhythmia detection. As health systems and payers increasingly focus on reducing avoidable acute care utilization, the growing body of real-world evidence supporting Zio's ability to enable earlier diagnosis and more efficient care delivery continues to differentiate our platform. As we enter 2026, our priorities remain consistent: scale our platform globally, advance our next-generation product roadmap, deepen our predictive AI capabilities, and execute with financial discipline to drive sustained, long-term value for patients, physicians, providers, and shareholders."

**Fourth Quarter 2025 Financial Results**

Revenue for the three months ended December 31, 2025, increased 27.1% to $208.9 million, from $164.3 million during the same period in 2024. The increase was driven primarily by increased volume of Zio Services resulting from increased demand with additional contribution from favorable pricing and mix.

Gross profit for the fourth quarter of 2025 was $148.1 million, up from $115.1 million during the same period in 2024, while gross margin was 70.9% as compared to 70.0% during the same period in 2024. The improvement in gross margin was primarily driven by scale, manufacturing efficiencies, and favorable pricing and mix.

Operating expenses for the fourth quarter of 2025 were $145.8 million, compared to $119.2 million for the same period in 2024. Adjusted operating expenses for the fourth quarter of 2025 were $140.0 million, compared to $116.7 million during the same period in 2024. The increase in adjusted operating expenses, period over period, was driven by an increase in volume-related costs to serve and investments to drive future revenue growth.

Net income for the fourth quarter of 2025 was $5.6 million, or a diluted income of $0.17 per share, compared with net loss of $1.3 million, or a diluted loss of $0.04 per share, for the same period in 2024.

------

**Exhibit 99.1**

**Full Year 2025 Financial Results**

Revenue for the year ended December 31, 2025, increased 26.2% to $747.1 million, from $591.8 million in 2024. The increase in revenue was primarily due to increased volume of Zio services provided as a result of increased demand.

Gross profit for the year was $527.3 million, up from $407.5 million in 2024, while gross margin was 70.6%, an improvement from 68.9% in 2024. The improvement in gross margin was primarily driven by scale and operational efficiencies leading to lower costs per unit to serve a higher volume of patients compared to the prior year.

Operating expenses for the year were $584.7 million, an increase of 11.8% compared to 2024. The increase was mainly due to headcount-related costs and professional fees to fuel the growth in our business.

Net loss for 2025 was $44.6 million, or a diluted loss of $1.39 per share, compared with net loss of $113.3 million, or a diluted loss of $3.63 per share in 2024.

Unrestricted cash, cash equivalents and marketable securities were $583.8 million as of December 31, 2025.

**2026 Guidance** 

For the full year 2026, iRhythm expects revenue of $870 million to $880 million and adjusted EBITDA margin of 11.5% to 12.5%, reflecting continued volume-led growth, gross margin expansion, and operating leverage while maintaining disciplined investment in innovation and market expansion.

**Webcast and Conference Call Information**

iRhythm's management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event, which will be available on the investors section of the Company's website at investors.irhythmtech.com.

**About iRhythm Holdings, Inc.**

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all.

As reported in the Form 8-K of iRhythm filed on January 12, 2026, the Company is the successor registrant pursuant to Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended, to iRhythm Technologies, Inc., a Delaware corporation ("iRhythm Technologies"), as a result of the completion of a holding company reorganization on January 12, 2026. As a result, the unaudited and audited financial results of the Company for all periods prior to January 12, 2026, are the unaudited and audited financial results of iRhythm Technologies and are being provided for the Company on a consolidated basis.

**Use of Non-GAAP Financial Measures**

We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per share, adjusted operating expenses, and free cash flow. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA margin estimates for full year 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.

Adjusted EBITDA excludes non-cash operating charges for stock-based compensation expense, changes in fair value of strategic investments, impairment and restructuring charges, business transformation costs, certain intellectual property litigation expenses and settlements, and loss on extinguishment of debt. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.

------

**Exhibit 99.1**

**Forward-Looking Statements**

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular these statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, international market expansion, anticipated productivity and quality improvements, and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled "Risk Factors" and elsewhere in our filings made with the Securities and Exchange Commission, including those on the Form 10-K expected to be filed on or about February 19, 2026. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

**Investor Contact**

Stephanie Zhadkevich

investors@irhythmtech.com

**Media Contact**

Kassandra Perry

mediarelations@irhythmtech.com

------

**Exhibit 99.1**

**IRHYTHM TECHNOLOGIES, INC.**

 **Consolidated Balance Sheets**

**(In thousands, except par value)**

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $236012 | $419597 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 347751 | 115956 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 75706 | 79941 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 21634 | 14039 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 21662 | 16286 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 702765 | 645819 |
| Property and equipment, net | 151599 | 125092 |
| Operating lease right-of-use assets | 41827 | 47564 |
| Restricted cash | 8358 | 8358 |
| Goodwill | 862 | 862 |
| Long-term strategic investments | 69913 | 61902 |
| Other assets | 44718 | 41852 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1020042 | $931449 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $2256 | $7221 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 128747 | 84900 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 4201 | 2932 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, current portion | 16686 | 15867 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 151890 | 110920 |
| Long-term senior convertible notes | 649504 | 646443 |
| Other noncurrent liabilities | 908 | 8579 |
| Operating lease liabilities, noncurrent portion | 64994 | 74599 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 867296 | 840541 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value – 5,000 shares authorized; none issued and outstanding at December 31, 2025 and 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value – 100,000 shares authorized; 32,526 shares issued and 32,297 shares outstanding at December 31, 2025, respectively; and 31,621 shares issued and 31,392 shares outstanding at December 31, 2024 | 32 | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 980757 | 874607 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 403 | 165 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (803446) | (758895) |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost; 229 shares at December 31, 2025 and 2024, respectively | (25000) | (25000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 152746 | 90908 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1020042 | $931449 |

---

------

**Exhibit 99.1**

**IRHYTHM TECHNOLOGIES, INC.**

**Consolidated Statements of Operations**

**(In thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **(Unaudited)**<br>**Three Months Ended December 31,** | **(Unaudited)**<br>**Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue, net | $208890 | $164325 | $747138 | $591839 |
| Cost of revenue | 60835 | 49257 | 219888 | 184308 |
| Gross profit | 148055 | 115068 | 527250 | 407531 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 21046 | 19081 | 84610 | 71459 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquired in-process research and development | 740 | 302 | 3036 | 32371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 122004 | 99768 | 492553 | 418565 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment charges | 1979 |  | 4458 | 641 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 145769 | 119151 | 584657 | 523036 |
| Income (loss) from operations | 2286 | (4083) | (57407) | (115505) |
| Interest and other income, net: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 5337 | 5740 | 21521 | 21938 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (3322) | (3320) | (13154) | (12821) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt |  |  |  | (7589) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 1725 | 481 | 5442 | 1253 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total interest and other income, net | 3740 | 2901 | 13809 | 2781 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) before income taxes | 6026 | (1182) | (43598) | (112724) |
| Income tax provision | 447 | 151 | 953 | 565 |
| Net income (loss) | $5579 | $(1333) | $(44551) | $(113289) |
| Net income (loss) per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.17 | $(0.04) | $(1.39) | $(3.63) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.17 | $(0.04) | $(1.39) | $(3.63) |
| Weighted-average shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 32258 | 31343 | 32004 | 31196 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 33332 | 31343 | 32004 | 31196 |

---

------

**Exhibit 99.1**

**IRHYTHM TECHNOLOGIES, INC.**

**Reconciliation of GAAP to Non-GAAP Financial Information**

**(In thousands, except per share data)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Adjusted EBITDA reconciliation\*** |  |  |  |  |
| Net income (loss)<sup>1</sup> | $5579 | $(1333) | $(44551) | $(113289) |
| Interest expense | 3322 | 3320 | 13154 | 12821 |
| Interest income | (5337) | (5740) | (21521) | (21938) |
| Changes in fair value of strategic investments | (1822) | (843) | (5711) | (1902) |
| Income tax provision | 447 | 151 | 953 | 565 |
| Depreciation and amortization | 5254 | 5289 | 20742 | 20715 |
| Stock-based compensation | 21106 | 16008 | 88283 | 75978 |
| Impairment charges | 1979 |  | 4458 | 641 |
| Business transformation costs | 692 | 2416 | 3033 | 11072 |
| Intellectual property litigation costs<sup>2</sup> | 3070 |  | 10070 |  |
| Loss on extinguishment of debt |  |  |  | 7589 |
| Adjusted EBITDA | $34290 | $19268 | $68910 | $(7748) |
| **Adjusted net income (loss) reconciliation\*** |  |  |  |  |
| Net income (loss), as reported<sup>1</sup> | $5579 | $(1333) | $(44551) | $(113289) |
| Impairment charges | 1979 |  | 4458 | 641 |
| Business transformation costs | 692 | 2416 | 3033 | 11072 |
| Intellectual property litigation costs<sup>2</sup> | 3070 |  | 10070 |  |
| Changes in fair value of strategic investments | (1822) | (843) | (5711) | (1902) |
| Loss on extinguishment of debt |  |  |  | 7589 |
| Tax effect of adjustments<sup>3</sup> | 211 |  | (89) |  |
| Adjusted net income (loss) | $9709 | $240 | $(32790) | $(95889) |
| **Adjusted net income (loss) per share reconciliation\*** |  |  |  |  |
| Net income (loss) per share, as reported<sup>1</sup> | $0.17 | $(0.04) | $(1.39) | $(3.63) |
| Impairment charges per share | 0.06 |  | 0.14 | 0.02 |
| Business transformation costs per share | 0.02 | 0.08 | 0.09 | 0.35 |
| Intellectual property litigation costs per share<sup>2</sup> | 0.09 |  | 0.31 |  |
| Changes in fair value of strategic investments per share | (0.05) | (0.03) | (0.18) | (0.06) |
| Loss on extinguishment of debt per share |  |  |  | 0.24 |
| Tax effect of adjustments per share<sup>3</sup> | 0.01 |  |  |  |
| Adjusted diluted net income (loss) per share | $0.29 | $0.01 | $(1.03) | $(3.08) |
| Weighted-average shares, basic | 32258 | 31343 | 32004 | 31196 |
| Weighted-average shares, diluted | 33332 | 31710 | 32004 | 31196 |

---

------

**Exhibit 99.1**

**IRHYTHM TECHNOLOGIES, INC.**

**Reconciliation of GAAP to Non-GAAP Financial Information (continued)**

**(In thousands)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| **Adjusted operating expenses reconciliation\*** | **2025** | **2024** | **2025** | **2024** |
| Operating expenses, as reported | $145769 | $119151 | $584657 | $523036 |
| Impairment charges | (1979) |  | (4458) | (641) |
| Business transformation costs | (692) | (2416) | (3033) | (11072) |
| Intellectual property litigation costs<sup>2</sup> | (3070) |  | (10070) |  |
| Adjusted operating expenses | $140028 | $116735 | $567096 | $511323 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Free cash flow reconciliation\*** | | | | |
| Net cash provided by operating activities | $26212 | $19232 | $80863 | $3390 |
| Purchases of property and equipment | (11723) | (6844) | (46342) | (33942) |
| Free cash flow | $14489 | $12388 | $34521 | $(30552) |

---

\*Certain numbers expressed may not sum due to rounding.

<sup>1</sup>Net income (loss) for the three and twelve months ended December 31, 2025, includes acquired in-process research and development expense of $0.7 million and $3.0 million, respectively. Net loss for the three and twelve months ended December 31, 2024, includes acquired in-process research and development expense of $0.3 million and $32.4 million, respectively.

<sup>2</sup> Excludes third-party attorneys' fees and expenses associated with patent litigation brought against the Company by Welch Allyn, Inc. and Bardy Diagnostics, Inc., subsidiaries of Baxter International, Inc.

<sup>3</sup> Income tax impact of Non-GAAP adjustments listed.

<br>